Cancer Alliance Data Pack
|
|
- Charleen Lyons
- 5 years ago
- Views:
Transcription
1 Surrey and Sussex Cancer Alliance Data Pack By February 18 Version 1.1 Produced by the Cancer Alliance Data, Evidence and Analysis Service (CADEAS) For any enquiries contact:
2 Contents 1 Summary of key findings 2 About the data pack 3 How to interpret the data 4 Further data releases 5 Alliance key indicators grid 6 Alliance key indicators grid, with values 7 Alliance indicators by Outcome indicators One-year age-standardised net cancer survival Under-75 age-standardised cancer mortality rate Cancer prevalence Patient experience: rating of overall care Pathway indicators Bowel screening uptake and coverage Breast screening uptake and coverage Cervical screening coverage Cancers diagnosed through an emergency presentation Routes to diagnosis: breast, colorectal, lung and prostate cancer Cancer waiting times: two-week wait and 62-day standard Age-standardised cancer incidence rate Cancers diagnosed at stage 1+2 Cancers staged Median waiting times: prostate, colorectal and lung cancer 8 Annex of data sources This data pack uses information provided by patients and collected by the NHS as part of their care and support Version Number Detail Date 1. Initial release 12/2/ Text in the pack has been updated to reflect change from internal to public use /11/18 CADEAS Alliance Data Pack by 2
3 1. Summary of key findings The Surrey and Sussex Cancer Alliance The latest available data on some key cancer indicators suggest the standard of cancer care in the Cancer Alliance was mixed. Guildford and Waverly and Horsham and Mid Sussex s had the most indicators that were better than the England average. In contrast, Brighton and Hove, and North West Surrey s performed worse than the England averages on a number of indicators. Screening: Screening uptake and coverage were generally similar to, or better than, the England average across all s, with the exception of Brighton and Hove, and North West Surrey s who performed below England levels across all screening programmes. Emergency presentations: Emergency presentations were in line with, or better than, the England average in all s except and and Farnham s. Cancer waiting times: Two-week waiting times were exceeded in all s, except in Horsham and Mid Sussex, where it was lower than expected. The 62-day standard was met in four s: Guildford and Waverley, and Farnham, Surrey Downs and s. Early diagnosis: The proportions of cancers diagnosed at an early stage was generally similar to England levels in all but two s ( and and Farnham s). In Horsham and Mid Sussex the proportion of early stage diagnoses was higher than the England average. Survival: One-year survival was mixed in the Alliance with the majority of s reporting better survival outcomes than England levels, with poorer survival in four s (Brighton and Hover,, and Seaford, and Hastings and Rother s). Mortality: Under-75 mortality was similar to, or better than, the England average in all s. Patient experience: Patient reported experience of care was in line with the England level., except in, where it was better. CADEAS Alliance Data Pack by 3
4 2. About the data pack Cancer Alliances were formed as a result of recommendations in the 15 Independent Cancer Taskforce's Achieving World-Class Cancer Outcomes report. The 19 Alliances lead on the local delivery of the Cancer Strategy Implementation Plan, using a whole pathway and cross-organisational approach. CADEAS is a partnership between NHS England and Public Health England. The service supports Alliances with their data, evidence and analysis needs, to help drive evidencebased local decisions in the delivery of the Cancer Strategy Implementation Plan. This data pack aims to provide all Cancer Alliances in England with a snapshot of cancer in their local populations, with a breakdown by Clinical Commissioning Group (). 3. How to interpret the data This data pack highlights variation in cancer services across s in the Alliance. By using a colour coding system Alliances can identify where variation exists and prioritise areas for action. Data here should be considered alongside other sources of information for contextual and richer interpretation. The colour system: broadly, yellow indicates data are similar to the England level. Dark blue shows data are better than England and light blue indicates data are worse than England. Some metrics have been benchmarked to operational standards or expected values; these are denoted in the legends and in the Annex. All statistical tests for England benchmarking have been conducted using a 95% confidence level. At the time this report was made, there were three sites of the National Cancer Vanguard and 16 Alliances and the metric geography labels reflect this. Information on data sources can be found in the Annex. 4. Data releases CADEAS have released the following products,containing data metrics for the Cancer Alliances: A one-off level data pack for each of the 19 Cancer Alliances, to enable comparisons across s within an Alliance. Indicator summary grids comprising key indicators for each Alliance, available at, STP and Alliance levels. These are similar to the grids found in sections 5 and 6 of this data pack and are published by CADEAS on a monthly basis. CADEAS Alliance Data Pack by 4
5 One-year cancer survival Under 75 cancer mortality age-standardised rate Patient experience Bowel screening coverage (-69) Bowel screening uptake (-69) Bowel screening coverage (-74) Bowel screening uptake (-74) Breast screening coverage Breast screening uptake Cervical screening coverage Emergency presentations Cancer Waiting Times: Two-Week Wait Cancer Waiting Times: 62-day Standard Incidence age-standardised rate Early stage diagnosis Cancers staged 5. Cancer Alliance key indicators grid, by Statistically worse than England Excludes routes to diagnosis, prevalence and pathway median waiting times. This is due to the volume of data in these three areas. Please see data in rest of data pack CADEAS Alliance Data Pack by 5
6 One-year cancer survival Under 75 cancer mortality age-standardised rate Patient experience Bowel screening coverage (-69) Bowel screening uptake (-69) Bowel screening coverage (-74) Bowel screening uptake (-74) Breast screening coverage Breast screening uptake Cervical screening coverage Emergency presentations Cancer Waiting Times: Two-Week Wait Cancer Waiting Times: 62-day Standard Incidence age-standardised rate Early stage diagnosis Cancers staged 6. Cancer Alliance key indicators grid, by Statistically worse than England Excludes routes to diagnosis, prevalence and pathway median waiting times. This is due to the volume of data in these three areas. Please see data in rest of data pack CADEAS Alliance Data Pack by 6
7 Rate per, Survival (%) 7. Alliance indicators by Cancer survival One-year index of cancer survival, all cancers, adults diagnosed in 15 and followed up to Statistically worse than England Taskforce Ambition (75% by ) England (72.3%) Cancer mortality Age-standardised mortality rate for all cancers, patients under 75, Statistically worse than England England (136.6 per, population) CADEAS Alliance Data Pack by 7
8 < 1 yr 1 yrs - < 2 yrs Cases Crude Rates per, (cases / total population in 15) 2 yrs - < 5 yrs 5 yrs - < yrs yrs - < 15 yrs ,885 2,93 1, ,593 2,73 4,875 5,166 3,296 2, , ,384 1,548 1, ,694 1,99 1, , ,669 1,885 1, ,549 1, , ,614 1,741 1, , ,898 2, 1, ,649 1,877 1, ,28 1,123 2,6 3,73 1,678 1, ,218 1,93 2,473 3,13 2,41 1, , yrs - < 21 yrs < 1 yr 1 yrs - < 2 yrs 2 yrs - < 5 yrs 5 yrs - < yrs yrs - < 15 yrs 15 yrs - < 21 yrs Cancer prevalence Patients diagnosed with cancer between (inclusive) alive on the 31st December 15 (21-year prevalence) Number of cases and crude rates are in year bands representing time since diagnosis CADEAS Alliance Data Pack by 8
9 Average score from very poor () to very good () Cancer patient experience Patient overall rating of cancer care, case-mix adjusted, Statistically worse than England England (Score: 8.7) CADEAS Alliance Data Pack by 9
10 Bowel cancer screening, ages -69 % Persons, aged -69, screened for bowel cancer in last months (2.5 year coverage), 16/ Statistically worse than England England (57.5%) Persons, aged -69, screened for bowel cancer within 6 months of invitation (uptake), 16/17 % Statistically worse than England England (57.1%) CADEAS Alliance Data Pack by
11 Bowel cancer screening, ages -74 % Persons, aged -74, screened for bowel cancer in last months (2.5 year coverage), 16/ Statistically worse than England England (59.2%) Persons, aged -74, screened for bowel cancer within 6 months of invitation (uptake), 16/ % Statistically worse than England England (59%) CADEAS Alliance Data Pack by 11
12 Breast cancer screening % 9 8 Females, aged -, screened for breast cancer in last 36 months (3 year coverage), 16/ Statistically worse than England England (72.5%) % Females, aged -, screened for breast cancer within 6 months of invitation (uptake), 16/ Statistically worse than England England (72.2%) CADEAS Alliance Data Pack by 12
13 Emergency Presentation (%) Cervical cancer screening Females, aged 25-64, attending cervical screening within target period (3.5 or 5.5 year coverage), 16/17 % Statistically worse than England England (72.1%) Emergency presentations Cancers diagnosed through emergency presentation, year to June Statistically worse than England England (19.4%) CADEAS Alliance Data Pack by 13
14 Routes to diagnosis Routes to diagnosis for breast cancer in England, 6-15 Screen Detected Managed Emergency Presentation Other Number of Cases 24% 63% 5% 8% 1,875 27% 61% 4% 9% 5,145 28% 61% 4% 8% % 55% 3% 11% 1,485 28% % 5% 7% 1,825 % 49% 5% 16% 1,777 27% 63% 5% 5% 1,83 29% 57% 4% 9% 1,672 26% % 4% 11% 1,939 24% 54% 4% 19% 1,565 28% 56% 4% 13% 2,791 % 54% 3% 12% 2,594 27% 55% 3% 15% 791 Routes to diagnosis for colorectal cancer in England, 6-15 Screen Detected Managed Emergency Presentation Other Number of Cases 5% 44% 28% 23% 1,431 7% 57% 22% 14% 4,43 6% 54% 22% 18% 562 7% 51% 21% 21% 1,134 6% 61% 22% 12% 1,646 8% 54% 21% 17% 1,166 6% 55% 29% 11% 1,544 6% % 25% 19% 1,181 7% 48% 22% 22% 1,383 8% 52% % % 1,225 7% 49% 26% 18% 2,256 6% 53% 22% 19% 1,867 9% 48% 23% % 571 Statistically worse than England CADEAS Alliance Data Pack by 14
15 Routes to diagnosis Routes to diagnosis for lung cancer in England, 6-15 Managed Emergency Presentation Other Number of Cases 49% 36% 15% 1,515 55% 32% 13% 3,548 41% 45% 14% % 43% 16% % 34% 13% 1,368 % 35% 16% % 39% 12% 1,464 % 34% 16% % 38% 17% 1,1 29% 33% 39% 1,57 48% 34% 18% 1,895 47% 37% 16% 1,545 32% 33% 35% 482 Routes to diagnosis for prostate cancer in England, 6-15 Managed Emergency Presentation Other Number of Cases 77% % 13% 1,572 81% 6% 13% 4,695 79% 8% 13% % 9% 18% 1,215 77% % 13% 1,2 76% 7% 18% 1,7 8% % % 1,557 77% 9% 13% 1,1 76% 8% 16% 1,7 69% 6% 24% 1,272 % 12% 18% 2,275 69% 9% 22% 2,251 % 7% 24% 679 Statistically worse than England CADEAS Alliance Data Pack by 15
16 Total Seen Q3: Oct-Dec 16/17 Q4: Jan-Mar 16/17 Q1: Apr-Jun 17/18 Q2: Jul-Sep 17/18 Seen After 14 Days Seen Within 14 Days Total Seen Seen After 14 Days Seen Within 14 Days Total Seen Seen After 14 Days Seen Within 14 Days Total Seen Seen After 14 Days Seen Within 14 Days 2, % 2, % 2, % 2, % 4, % 4, % 4, % 4, % 1, % 1, % 1, % 1, % 1, % 1, % 1, % 1, % 2, % 2, 25 99% 2, % 2, % 1,321 3 % 1, % 1, % 1, % 1, % 1, % 1,938 95% 1, % 1, % 1, % 1, % 1, % 2, % 2, % 2, % 2, % 1, % 1, % 1, % 1, % 2, % 2, % 2, % 2, % 2, % 2, 58 97% 2,6 5 95% 2, % % % % % Cancer waiting times: two-week wait Two-week wait for all cancers, year to Sep 17 CADEAS Alliance Data Pack by 16
17 Total Seen Q3: Oct-Dec 16/17 Q4: Jan-Mar 16/17 Q1: Apr-Jun 17/18 Q2: Jul-Sep 17/18 Seen After 62 Days Treated Within 62 Days Total Seen Seen After 62 Days Treated Within 62 Days Total Seen Seen After 62 Days Treated Within 62 Days Total Seen Seen After 62 Days Treated Within 62 Days % % % % % % % % % % % % % % % % % % % % % % % % % 164 % % % % % % % % 6 81% % % % % % % % % % % 7 9% % % % % 6 88% % % Cancer waiting times: 62-day standard 62-day standard for all cancers, year to Sep 17 CADEAS Alliance Data Pack by 17
18 Patients seen within 62 days (%) Patients seen within 14 days (%) Cancer waiting times: two-week wait 9 8 Two-Week Wait for all cancers, year to Sep Same as operational standard Below operational standard Above operational standard England (94.5%) Operational Standards (93%) Cancer waiting times: 62-day standard day wait for first treatment for all cancers, year to Sep Same as operational standard Below operational standard atandard Above operational standard England (81.6%) Operational Standards (85%) CADEAS Alliance Data Pack by 18
19 Early Diagnosis (%) Rate per, Cancer incidence 8 Age-standardised incidence rate for all cancers, Statistically worse than England England (5 per, population) Early diagnosis Cancer diagnosed at stage 1 or 2 as a proportion of all staged and unstaged cancers ( cancers only*), year to December Statistically worse than England England (52.6%) * Invasive malignancies of breast, prostate, colorectal, lung, bladder, kidney, ovary and uterus, non-hodgkin lymphomas, and melanomas of skin CADEAS Alliance Data Pack by 19
20 Median number of days Cancers Staged (%) Cancers staged Cancers staged ( cancers*), Statistically worse than England England (9.83%) * Invasive malignancies of breast, prostate, colorectal, lung, bladder, kidney, ovary and uterus, non-hodgkin lymphomas, and melanomas of skin Median waiting times: Colorectal cancer pathway Median waiting times (days): Colorectal cancer pathway, Referral to First Seen First Seen to Diagnosis Diagnosis to MDT MDT to Treatment CADEAS Alliance Data Pack by
21 Median number of days Median number of days Median waiting times: Lung cancer pathway Median waiting times (days): Lung cancer pathway, Referral to First Seen First Seen to Diagnosis Diagnosis to MDT MDT to Treatment Median waiting times: Prostate cancer pathway Median waiting times (days): Prostate cancer pathway, Referral to First Seen First Seen to Diagnosis Diagnosis to MDT MDT to Treatment CADEAS Alliance Data Pack by 21
22 8. Annex: Data sources Indicator Year Source Cancer outcomes One-year cancer survival Under-75 mortality agestandardised rate Prevalence Patients overall rating of cancer care (case-mix adjusted) Patients followed up in year prevalence patients who are alive on the 31st December alcare/conditionsanddiseases/bulletins/indexofcancersurvivalforclinicalc ommissioninggroupsinengland/adultsdiagnosedto15andfollowed upto16/relateddata Benchmark: England Extracted from CancerStats Benchmark: England National Cancer Patient Experience Survey Benchmark: Expected values Cancer pathway Screening uptake and coverage Two-week waiting time standard 62-day waiting time standard Cancers diagnosed through emergency presentation Routes to diagnosis (all malignant neoplasms) 16/17 Quarterly Q3 16/17 to Q2 17/18; Year to Q2 17/18 Quarterly Q3 16/17 to Q2 17/18; Year to Q2 17/18 Year to Q Incidence rate 15 Cancers diagnosed at stage 1 & 2 (note this is based on the IAF definition and includes data for tumours only) Cancers staged 15 Pathways (median times) 15 Year to Q3 16 Confidence interval based on Wilson method Benchmark: England Benchmark: Operational Standard Benchmark: Operational Standard Confidence interval based on Wilson method Benchmark: England Benchmark: England Extracted from CancerStats Benchmark: England Confidence interval based on Wilson method Benchmark: England Confidence interval based on Wilson method. Extracted from CAS Benchmark: England NCRAS analysis using CAS data, based on TSCT-NCRAS work, using the CWT field REFERRAL_DATE: CADEAS Alliance Data Pack by 22
Cancer Alliance Data Pack
Humber, Coast and Vale Cancer Alliance Data Pack By February 18 Version 1.2 Produced by the Cancer Alliance Data, Evidence and Analysis Service (CADEAS) For any enquiries contact: england.cadeas@nhs.net
More informationBreast Test Wales Screening Division Public Health Wales
Breast Test Wales Screening Division Public Health Wales Programme Level Agreement with Welsh Government Quarterly Report October - December Breast Test Wales - Quarterly Report October - December Service
More informationNICaN workshop: Colorectal Cancer Follow-up
NICaN workshop: Colorectal Cancer Follow-up The Changing Picture of Colorectal Cancer in Northern Ireland Dr Helen Coleman Lecturer in Cancer Epidemiology & CRUK Population Research Postdoctoral Fellow
More informationINFORMATION TO SUPPORT THE DEVELOPMENT OF THE LINCOLNSHIRE CANCER STRATEGY
INFORMATION TO SUPPORT THE DEVELOPMENT OF THE LINCOLNSHIRE CANCER STRATEGY Final draft January 212 Ann Ellis, Health Improvement Principal, NHS Lincolnshire Leanne Goulsbra, Senior Information Analyst,
More informationTransforming cancer care: the bigger picture and what's next
Transforming cancer care: the bigger picture and what's next Session plan Introduction and progress of the National Cancer Programme The future of NHS cancer care in the long term plan for cancer Discussion
More informationBreast Screening Data Stephen Scott Head of Informatics LCA
Breast Screening Data Stephen Scott Head of Informatics LCA stephenscott@nhs.net The London Cancer Alliance Overview 62 day screening to 1 st treatment performance Key surgical measures monitored by LCA
More informationContents [HEALTH PROFILES - QUARTERLY UPDATE BRIEFING AUGUST 2016] M.Foxcroft. Performance & Intelligence Team
M.Foxcroft Performance & Intelligence Team HEALTH PROFILES - QUARTERLY UPDATE BRIEFING AUGUST 2016 Public Health England has recently published a quarterly update to its Health Profiles, which provide
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationPennine Acute Hospitals NHS Trust. Advancing Quality Results October 2008 to December 2016
Pennine Acute Hospitals NHS Trust Advancing Quality Results October 2008 to December 2016 Pennine Acute Hospitals NHS Trust Participation Summary Y1 Y2 Y3 Y4 Y5 Y6 Acute Kidney Injury - - - - - - - Alcohol
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationBSA New Zealand Hawkes Bay District Health Board Coverage Report
BSA New Zealand Hawkes Bay District Health Board Coverage Report For the period ending 31 December 2016 Citation: Ministry of Health. February 2017. BSA New Zealand District Health Board Coverage Report:
More informationBrighton and Sussex University Hospitals NHS Trust Board of Directors. Mark Smith Chief Operating Officer
Meeting: Brighton and Sussex University Hospitals NHS Trust Board of Directors Date: 24 th August 2015 Board Sponsor: Paper Author: Subject: Mark Smith Chief Operating Officer Clinical Director and Directorate
More informationOFFICIAL. Achieving World-Class Cancer Outcomes: Taking the strategy forward Equality and Health Inequalities Analysis. May
Achieving World-Class Cancer Outcomes: Taking the strategy forward Equality and Health Inequalities Analysis May 2016 1 Achieving World-Class Cancer Outcomes: Taking the strategy forward Equality and Health
More informationGOVERNING BODY MEETING in Public 27 September 2017 Agenda Item 5.1
GOVERNING BODY MEETING in Public 27 September 2017 Agenda Item 5.1 Report Title NHS Eastern Cheshire CCG Cancer Strategy Appendix A NHS Eastern Cheshire CCG Cancer Strategy 2017-2021 draft 5 September
More informationWessex Cancer Alliance. Wessex Cancer Strategic Clinical Network
Wessex Cancer Alliance Wessex Cancer Strategic Clinical Network Chair : Tim Billington Friday 11 th September 2015 Patients are our priority Patients are people Perception versus what is said Pathways
More informationNational Cancer Programme: Living With and Beyond Cancer. Becky Clack Programme Manager, NHS England. September
National Cancer Programme: Living With and Beyond Cancer Becky Clack Programme Manager, NHS England September 2017 Contents 1 The Context 2 LWBC Early Priorities 3 Recovery Package & Stratified Follow-up
More informationCancer Waiting Times in NHSScotland
Cancer Waiting Times in NHSScotland 1 October to 31 December 2017 Publication date 27 March 2018 A National Statistics publication for Scotland This is a National Statistics Publication National Statistics
More informationCancer Waiting Times in NHSScotland
Publication Report Cancer Waiting Times in NHSScotland 1 April to 30 June 2017 Publication date 26 September 2017 A National Statistics Publication for Scotland Contents Introduction... 3 Main points...
More informationUsing Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer
Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer Dr Gill Lawrence, WM KIT, on behalf of Breast SSCRG Cancer Outcomes Conference, Brighton, June 2013
More informationShowcase: East of England understanding variation. Dr Rory Harvey Chair East of England Cancer Alliance
Showcase: East of England understanding variation Dr Rory Harvey Chair East of England Cancer Alliance Cancer Alliances Establishment of Alliances recommended by the Cancer Taskforce to: drive and support
More informationCancer Waiting Times in NHSScotland
Publication Report Cancer Waiting Times in NHSScotland 1 July to 30 September 2017 Publication date 12 December 2017 A National Statistics Publication for Scotland Contents Introduction... 3 Main points...
More informationRichard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead
GOVERNING BODY Agenda Item No. 08 Reference No. IESCCG 18-02 Date. 23 January 2018 Title Lead Chief Officer Author(s) Purpose Cancer Services Update Richard Watson, Chief Transformation Officer Dr P Holloway,
More informationSouth West Cancer Alliances Rapid Diagnostic Pathway for Lung Cancer Project Evaluation
Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance Peninsula Cancer Alliance South West Cancer Alliances Rapid Diagnostic Pathway for Lung Cancer Project Evaluation Peninsula Thoracic-Oncology
More informationNational Cancer Programme: Living With and Beyond Cancer
National Cancer Programme: Living With and Beyond Cancer Sarah Benger Senior Programme Manager, NHS England February 2017 Introduction: The Independent Cancer Taskforce Aim: To improve cancer services
More informationNational Update: Living With and Beyond Cancer Implementing Strategic Priority 4 of the National Cancer Taskforce
National Update: Living With and Beyond Cancer Implementing Strategic Priority 4 of the National Cancer Taskforce Duleep Allirajah Head of Policy, Macmillan Cancer Support Total Prevalence - now Total
More informationThe Single Cancer Pathway
The Single Cancer Pathway Background and Case for Change Case for Change (1) Broadly patient experience of cancer services in Wales is good: 93% of patients rate their care as 7/10 or better (WPES) But
More informationNational Cancer Intelligence Network data usage. 17 November 2015 Veronique Poirier Principal Cancer Analyst NCIN
National Cancer Intelligence Network data usage 17 November 2015 Veronique Poirier Principal Cancer Analyst NCIN Overview Cancer registration in England Data collection for brain tumours in England Incidence
More informationWHERE NEXT FOR CANCER SERVICES IN SCOTLAND?
WHERE NEXT FOR CANCER SERVICES IN SCOTLAND? AN EVALUATION OF PRIORITIES TO IMPROVE CANCER OUTCOMES Research finalised in June 2016 Published in June 2017 Where next for cancer services in Scotland? 1 ABOUT
More informationIdentifying and counting people living with treatable but not curable cancer
Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people
More informationSupplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
More informationHas the UK had a double epidemic?
Has the UK had a double epidemic? Dr Rodney P Jones Healthcare Analysis & Forecasting www.hcaf.biz hcaf_rod@yahoo.co.uk Introduction Outbreaks of a new type of epidemic, possibly due to immune manipulation,
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1-: Annual Report of the National Cancer Registry ABBREVIATIONS % CI % confidence interval APC Annual percentage change ASR Age-standardised rate (European standard population) CNS Central
More informationCancer survival by stage at diagnosis in Wales,
Cancer survival by stage at diagnosis in Wales, 2011-2014 Welsh Cancer Intelligence and Surveillance Unit www.wcisu.wales.nhs.uk Latest available one-year net cancer survival by stage at diagnosis official
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2012-2016) AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016) Male Female Both sexes Male Female Both sexes 4,607 4,632 9,240 1 2,238 2,036 4,274
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2017 First published in June 2004, revised with each National Statistics publication Next due for revision October 2017 Information Services Division NHS National Services Scotland
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1994-213: Annual Report of the National Cancer Registry 215 Page 3 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard
More informationCancer in the South West Peninsula - a baseline assessment
Cancer in the South West Peninsula - a baseline assessment 1 The Cancer Reform Strategy 1.1 The Cancer Reform Strategy, published in December 2007 1, built on the progress already achieved since the publication
More informationCancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012
Cancer Outcomes and Services Dataset What is COSD? Skin Cancers Workshop October 2012 17 years ago......cancer registration and careful monitoring of treatment and outcomes are essential... Calman-Hine
More information5.2 Main causes of death Brighton & Hove JSNA 2013
Why is this issue important? We need to know how many people are born and die each year and the main causes of their deaths in order to have well-functioning health s. 1 Key outcomes Mortality rate from
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2011-2015) AVERAGE NUMBER OF DEATHS PER YEAR (2011-2015) Male Female Both sexes Male Female Both sexes 4,557 4,516 9,073 1 2,196 1,984 4,180
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.15.12.2016/04 Title: Taking the cancer strategy forward: programme update Lead Director: Professor Sir Bruce Keogh, National Medical Director Cally Palmer, National Cancer
More informationConsultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation
Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation Summary Between January and March 2014, NHS England consulted on a proposed change to the timetable
More informationAuthor: Dr Tina George Website:
A Awareness & Early Diagnosis Clinical Advisory Group (CAG) FINAL MEETING Output from Workshop Discussions on Implementing the Cancer Strategy: Summary Report & Suggested Actions for Cancer Alliances South
More informationConsultation on publication of new cancer waiting times statistics Summary Feedback Report
Consultation on publication of new cancer waiting times statistics Summary Feedback Report Information Services Division (ISD) NHS National Services Scotland March 2010 An electronic version of this document
More informationUnderstanding lymphoma: the importance of patient data
Understanding lymphoma: the importance of patient data Introduction what is a cancer registry and why is it important? Cancer registries collect detailed, personalised information and data about cancer
More informationTableau user guide for all Official Statistics
Health Intelligence Division, Public Health Wales Uned Deallusrwydd a Gwyliadwriaeth Canser Cymru Cyfadran Deallusrwydd Iechyd, Iechyd Cyhoeddus Cymru Tableau user guide for all Official Statistics There
More informationGetting it right: Approaches to promoting earlier diagnosis of cancer The national perspective
Getting it right: Approaches to promoting earlier diagnosis of cancer The national perspective Housekeeping Toilets Fire alarm Tea and Coffee Wifi: MSE-meeting rooms Password: mselondon Twitter - #gettingitright
More informationCancer and Data in the New NHS May Di Riley, Director Clinical Outcomes
Cancer and Data in the New NHS May 2011 Di Riley, Director Clinical Outcomes Overarching NHS context Financial constraints White Paper GP Commissioning/Commissioning Board Public Health England National
More informationCANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY
CANCER IN IRELAND 1994-2016 with estimates for 2016-2018: ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY 2018 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised
More informationNHS Bowel Cancer Screening Programme in Merseyside: Till Receipt Awareness Campaign in 2014
NHS Bowel Cancer Screening Programme in Merseyside: Till Receipt Awareness Campaign in 2014 Screening & Imms Team\Cancer Screening\2-Year Plan for Uptake Rates\BCSP Till Receipt Campaign Mar-Jun14.docx
More informationCancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
More informationVariation in optimal pre-diagnostic pathway in lung cancer patients in 2013 & 2014 using cancer registrations and the diagnostic imaging dataset
Variation in optimal pre-diagnostic pathway in lung cancer patients in 2013 & 2014 using cancer registrations and the diagnostic imaging dataset Clare Pearson Senior Cancer Information Analyst, ACE Programme,
More informationParity: Innovation in Practice
Parity: Innovation in Practice Karen Turner Director of Mental Health 11 February 2016 Why does parity matter? 1:4 adults experience at least one diagnosable mental health problem a year 1:10 children
More informationINFORMATION TO SUPPORT THE DEVELOPMENT OF THE LINCOLNSHIRE CANCER STRATEGY
INFORMATION TO SUPPORT THE DEVELOPMENT OF THE LINCOLNSHIRE CANCER STRATEGY Refreshed March 2013 Ann Ellis, Health Improvement Principal, NHS Lincolnshire Andrew Smith, Information Analyst, NHS Lincolnshire
More informationCANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND
12 March 2019 CANCER INCIDENCE AND SURVIVAL STATISTICS FOR NORTHERN IRELAND 1993-2017 Official Statistics on cancers diagnosed in Northern Ireland during 1993-2017 were published today. This release provides
More informationTransforming Cancer Services Team
Transforming Cancer Services Team Healthy London Partnership Annual Report 2016/17 July 2017 Supported by and delivering for London s NHS, Public Health England and the Mayor of London Contents Who we
More informationNHS Diabetes Prevention Programme: Expression of interest to participate in the first wave of national implementation
NHS Diabetes Prevention Programme: Expression of interest to participate in the first wave of national implementation Name of organisation(s) making this application South East (Kent, Medway, Surrey &
More informationNational Cancer Statistics in Korea, 2014
National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored
More informationOne Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
More informationTrust Board of Directors Public. Denise Gale. For Assurance and Information NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE
NLG(18)014 DATE OF MEETING 30 January 2018 REPORT FOR Trust Board of Directors Public REPORT FROM Richard Sunley, Deputy Chief Executive CONTACT OFFICER Denise Gale SUBJECT Cancer Performance and Backlog
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates NHS Harrow CCG Profile Version: 3.5 Ref No: P662 Date: March 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy McMeeking,
More informationSTATISTICAL PRESS NOTICE. DIRECT ACCESS AUDIOLOGY REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA January 2019
Thursday 21 March 2019 STATISTICAL PRESS NOTICE DIRECT ACCESS AUDIOLOGY REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA January 2019 Main Points Data are published on Direct Access Audiology patients whose
More informationCheshire and Merseyside Cancer Alliance. Helen Porter Director of Nursing and Quality 19 th April 2017
Cheshire and Merseyside Cancer Alliance Helen Porter Director of Nursing and Quality 19 th April 2017 Independent Cancer Taskforce Published five year strategy for cancer in July 2015 with aim to improve
More informationCancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
More informationCommissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview.
Commissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview. Document Title An Overview of Commissioning Living with and Beyond Cancer in Yorkshire and Humber Version number: 1 First
More informationNCIN Conference Feedback 2015
NCIN Conference Feedback 2015 Parallel Sessions Treatments (Black type is the topic; blue type are comments) The use of population and research data in the development of guidelines for cancer treatment
More informationTrust Board Meeting in Public: Wednesday 11 July 2018 TB
Trust Board Meeting in Public: Wednesday 11 July 2018 Title Integrated Performance Report: Month 2 Status History For information. The report provides a summary of the Trust s performance against a range
More informationReferral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report
Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report 1 Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual
More informationLancashire & South Cumbria Cancer Alliance Delivery Plan for
Lancashire & South Cumbria Cancer Alliance Delivery Plan for 2018-2019 1 Table of Contents FORWARD.5 SECTION 1 - INTRODUCTION... 6 1.1 - Local Context... 7 SECTION 2 - ORGANISATIONAL STRUCTURES... 12 2.1
More informationWirral University Teaching Hospital NHS Foundation Trust. Advancing Quality Results October 2008 to June 2017
Wirral University Teaching Hospital NHS Foundation Trust Advancing Quality Results October 2008 to June 2017 Wirral University Teaching Hospital NHS Foundation Trust Participation Summary Y1 Y2 Y3 Y4 Y5
More informationBritain against Cancer APPG Cancer Meeting 2009 Research & Technologies Workshop
Britain against Cancer APPG Cancer Meeting 2009 Research & Technologies Workshop Researching inequality and cancer - what we know and what requires further research David Forman, Michael Chapman, Jon Shelton
More informationUK Complete Cancer Prevalence for 2013 Technical report
UK Complete Cancer Prevalence for 213 Technical report National Cancer Registration and Analysis Service and Macmillan Cancer Support in collaboration with the national cancer registries of Northern Ireland,
More informationWHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected to be diagnosed
More informationWarrington And Halton Hospitals NHS Foundation Trust. Advancing Quality Results October 2008 to June 2017
Warrington And Halton Hospitals NHS Foundation Trust Advancing Quality Results October 2008 to June 2017 Warrington And Halton Hospitals NHS Foundation Trust Participation Summary Y1 Y2 Y3 Y4 Y5 Y6 Acute
More informationAintree University Hospital NHS Foundation Trust. Advancing Quality Results October 2008 to June 2017
Aintree University Hospital NHS Foundation Trust Advancing Quality Results October 2008 to June 2017 Aintree University Hospital NHS Foundation Trust Participation Summary Y1 Y2 Y3 Y4 Y5 Y6 Acute Kidney
More informationAintree University Hospital NHS Foundation Trust. Advancing Quality Results October 2008 to December 2017
Aintree University Hospital NHS Foundation Trust Advancing Quality Results October 2008 to December 2017 Aintree University Hospital Participation Summary Y1 Y2 Y3 Y4 Y5 Y6 Acute Kidney Injury - - - -
More informationProgress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England
Report by the Comptroller and Auditor General Department of Health, NHS England and Public Health England Progress in improving cancer services and outcomes in England HC 949 SESSION 2014-15 15 JANUARY
More informationCommissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013
Commissioning Cancer Services Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013 The Health & Social Care Bill (27 th March 2012) Two New Organisations NHS Commissioning Board (NHS CB)
More informationNHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014
NHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014 March 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales
More informationLung Cancer and the Cancer Alliance DR JAMES RAMSAY
Lung Cancer and the Cancer Alliance DR JAMES RAMSAY Background Lung cancer is the second commonest cancer in the UK (37,000 new cases in England each year). Commonest cause of cancer death (28,500 people
More informationWirral Cancer Strategy
Wirral Cancer Strategy 2017-2020 Wirral Strategic Cancer Partnership Contents Introduction 3 Cancer Strategy 2014 2016 Progress Update 4 The Current Challenges 5 Our Vision 6 Developing the Strategy 7
More informationBETTER CANCER CARE AND THE FUTURE PROVISION OF CANCER CARE IN NHS LANARKSHIRE
NHS Lanarkshire Board Meeting Wednesday 23rd November Boardroom, Kirklands Corporate HQ NHS Lanarkshire Headquarters, Kirklands Fallside Road, Bothwell G71 8BB www.nhslanarkshire.co.uk BETTER CANCER CARE
More informationBurden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates NHS Lambeth CCG Profile Version: 3.3 Ref No: P662 Date: March 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy McMeeking,
More informationStreamlining the lung diagnostic pathway (A87)
Streamlining the lung diagnostic pathway (A87) Crawley CCG with Surrey and Sussex Healthcare NHS Trust Evaluation January 2017 Summary A new Straight-to-CT pathway for patients with an abnormal CXR result
More informationExploring the healthcare cost implications of cancer stage. England level modelling
Exploring the healthcare cost implications of cancer stage England level modelling Rachel White (Rwhite@macmillan.org.uk) Thursday 22 nd September 2016 What we re covering Modelling methods Results - variation
More informationUpper Valleys Cluster Public Health Profile V1
Upper Valleys Cluster Public Health Profile 2016 2017 V1 This profile aims to inform the development of the QOF Practice and Cluster Development Plans with local and national data relating to the three
More informationAn Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
More informationOutcomes from Local Cancer Campaigns Survey February 2016
Outcomes from Local Cancer Campaigns Survey February 2016 Purpose The purpose of this report is for the Clinical Network and our key stakeholders to understand if Local Authorities have identified specific
More informationComplete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting
Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting Eric B. Durbin, DrPH, MS, Director of Cancer Informatics Frances E. Ross, CTR,
More informationCancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
More information7.14 Young Person and Adult (YPA) Screening Programmes
7. ADULT SECTION 7.14 Young Person and Adult (YPA) Screening Programmes Screening is a process of identifying apparently healthy people who are at increased risk of a disease or condition, to offer information,
More informationColorectal Cancer Screening
Colorectal Cancer Screening December 5, 2017 Connecticut Cancer Partnership 14th Annual Meeting Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director, Cancer Genetics and Prevention Program
More informationRoyal Liverpool And Broadgreen University Hospitals NHS Trust. Advancing Quality Results October 2008 to June 2017
Royal Liverpool And Broadgreen University Hospitals NHS Trust Advancing Quality Results October 2008 to June 2017 Royal Liverpool And Broadgreen University Hospitals NHS Trust Participation Summary Y1
More informationMacmillan-NICR Partnership: GP Federation Cancer Profiles (with Prevalence )
Macmillan-NICR Partnership: GP Federation Cancer Profiles 2011-2015 (with Prevalence 1993-2015) 1 C a n c e r S t a t i s t i c s b y G P F e d e r a t i o n a r e a : 2 0 1 1-2015 Table of Contents Introduction...
More informationBrighton and Hove Cancer Strategy P a g e
Brighton and Hove Cancer Strategy 2017 2020 1 P a g e Contents Section 1 Introduction Section 2 Prevention Section 3 Early Diagnosis Section 4 Patient Experience Section 5 Living with and beyond Cancer
More information18 Week 92% Open Pathway Recovery Plan and Backlog Clearance
18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted
More informationCancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
More informationA research briefing paper by Macmillan Cancer Support
A research briefing paper by Macmillan Cancer Support Introduction Key findings 3 People with cancer are surviving longer 4 Median survival time has seen dramatic improvement for some cancers 5 Median
More information